Last year saw remarkable advances, with seven products approved by the FDA, and currently 500 products are in the U.S. pipeline, with 10 to 20 new approvals expected in 2025.
It is essential to keep abreast of guidelines, resistance patterns, and diagnostic tools as well as to evaluate the literature and make recommendations on agent selection, dosing, and duration.